Last reviewed · How we verify
Strontium Oxydatum (STRONTIUM)
At a glance
| Generic name | STRONTIUM |
|---|---|
| Sponsor | Q Biomed |
| Modality | Small molecule |
| Therapeutic area | Bone |
| Phase | FDA-approved |
| First approval | 2022 |
Approved indications
- Postmenopausal osteoporosis
Common side effects
Key clinical trials
- TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus (PHASE2)
- Clinical Performances of 3-different Tooth-colored Restorative Materials in Class-II Cavities (NA)
- Strontium-Hydroxyapatite Coated Mini-Screws: Antibacterial Effect and Stability (NA)
- Color Stability of S-PRG Resin-Based Light-Cure Varnish and Prophylaxis Paste on White Spot Lesions (NA)
- Root Caries Prevention Using Fluoride Varnish Fortified With SBGC (NA)
- Clinical Assessment of Giomer Based Technology Versus Smart Bioactive Restoration in Carious Class V Cavities (NA)
- Successful Pregnancy and Delivery After AOA (NA)
- Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Strontium Oxydatum CI brief — competitive landscape report
- Strontium Oxydatum updates RSS · CI watch RSS
- Q Biomed portfolio CI